Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. (RedHill) relates to the Notice and Proxy Statement for an Extraordinary General Meeting of Shareholders scheduled for October 26, 2020. The filing was submitted on September 22, 2020. RedHill is a biopharmaceutical company incorporated in Israel with its principal executive offices in Tel Aviv. The document solicits shareholder approval for seven specific proposals regarding corporate governance, executive compensation, and equity incentives.
Key Financial Metrics and Capital Structure
The filing does not contain a financial statement or report on revenue, profit, cash flow, or debt for a specific reporting period. However, it provides the following capital structure data as of September 21, 2020:
- Outstanding Ordinary Shares: 374,086,048
- Outstanding American Depository Shares (ADSs): 37,408,604
- Par Value: NIS 0.01 per Ordinary Share
- Record Date for Voting: September 22, 2020
Specific financial thresholds are mentioned as conditions for option repricing, including targets for net revenues of $75 million to $130 million and negative EBITDA limits ranging from $20 million to $55 million for the years 2020 through 2022.
Material Changes and Proposed Actions
The filing outlines seven proposals to be voted upon, representing material changes to the company's policies and executive agreements:
- D&O Insurance Policy Amendment: Removal of the $2 million annual cap on Directors and Officers (D&O) insurance premiums due to rising market costs and increased litigation risks in the life science sector.
- Forum Selection Provision: Amendment to the Articles of Association to designate U.S. federal courts as the exclusive forum for Securities Act claims and the Tel Aviv District Court for derivative actions and fiduciary duty claims.
- CEO Employment Terms (Dror Ben-Asher): Increase in annual base salary from NIS 1,260,000 (~$360,000) to NIS 2,310,000 (~$660,000), effective October 1, 2020. Additionally, the Change in Control (CIC) severance payment is increased to 18 months' salary (up from the standard 12 months for senior management).
- CCO Employment Terms (Rick Scruggs): Incorporation of the CIC Plan terms, entitling him to 6 to 12 months' salary upon a Change in Control depending on tenure.
- Option Repricing (Rick Scruggs): Repricing of 75,000 ADS options granted to Mr. Scruggs. The new exercise price will be 50% of the original price (not less than $6.00), with potential further reductions to $5.00 or $4.30 if specific revenue and EBITDA targets are met.
- Board Option Extension: Extension of the exercise period for 64,000 ADS options granted to Board members in 2014 by three years, until March 19, 2024.
- CEO Option Extension: Extension of the exercise period for 45,000 ADS options granted to Mr. Ben-Asher in 2014 by three years, until March 19, 2024.
Guidance, Outlook, and Risks
Management Commentary: Management justifies the D&O insurance amendment citing significant market changes and increased premiums for life science companies. The forum selection provision is proposed to consolidate litigation and avoid forum shopping. Executive compensation adjustments are attributed to the need to align with market benchmarks and recognize the leadership's contribution to strategic milestones.
Risks and Contingencies:
- Enforceability Risk: The filing notes uncertainty regarding whether courts will enforce the proposed exclusive forum selection provisions.
- Investor Limitation: The forum selection amendment may limit investors' ability to bring claims in judicial forums they find favorable.
- Performance Conditions: The repricing of options for Mr. Scruggs is contingent on the company meeting specific financial performance targets (revenue and EBITDA) in 2020, 2021, and 2022.
Key Facts for Investor Verification
- Voting Thresholds: Proposals 1, 3, and 7 require a majority vote of non-controlling shareholders without a personal interest, or a majority of all votes provided non-controlling opposition does not exceed 2% of total voting rights.
- Compensation Increase: Verify the impact of the CEO's base salary increase (approx. 83% increase) and the enhanced 18-month severance package on future cash burn.
- Option Dilution: Assess the dilution impact of repricing options for Mr. Scruggs and extending options for the Board and CEO, particularly given the potential for lower exercise prices based on performance metrics.
- Legal Precedent: Review the enforceability of the proposed forum selection clauses in light of recent Delaware Supreme Court rulings and potential challenges in U.S. federal courts.
- Meeting Logistics: Confirm the record date (September 22, 2020) and the deadline for proxy submission (October 22, 2020, for ADS holders) to ensure voting rights are preserved.